In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance

Diabetes

Volumn 47, Issue 12, 1998, Pages 1928-1934

  Pietzsch, Jens ^a   Julius, Ulrich ^a   Nitzsche, Sigrid ^a   Hanefeld, Markolf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PROINSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISOTOPE LABELING; LIPID COMPOSITION; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION;

EID: 0031737669     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.12.1928     Document Type: Article

References (52)

1. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325:373-381, 1991
2. Forte TM, McCall MR: The role of apolipoprotein AI-containing lipoproteins in atherosclerosis. Curr Opin Lipidol 5:354-364, 1994
3. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, Anderson JW, Kashyap ML, Schectman G: Lipid profiles in 8,500 men with coronary artery disease. Am J Cardiol 75:1195-1201, 1995
4. Wilt TJ, Rubins HB, Robins SJ, Riley WA, Collins D, Elam M, Rutan G, Anderson JW: Carotid atherosclerosis in men with low levels of HDL cholesterol. Stroke 28:1919-1925, 1997
5. Howard BV: Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28:613-628, 1987
6. Burchfiel CM, Hamman RF, Marshall JA, Baxter J, Kahn LB, Amirani JJ: Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study. Am J Epidemiol 131:57-70, 1990
7. Laws A, King AC, Haskell WL, Reaven GM: Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentrations in men. Arterioscler Thromb 11:1636-1642, 1991
8. Bavenholm P, Karpe F, Proudler A, Tornvall P, Crook D, Hamsten A: Association of insulin and insulin propeptides with an atherogenic lipoprotein phe- notype. Metabolism 44:1481-1488, 1995
9. Laakso M: Insulin resistance and coronary heart disease. Curr Opin Lipidol 7:217-226, 1996
10. Haffner SM, Miettinen H, Gaskill SP, Stern MP: Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia 39:1201-1207, 1996
11. Haffner SM, Gonzalez C, Mykkänen L, Stern MP: Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 40:830-837, 1997
12. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, Mykkänen L, Karter AJ, Hamman R, Saad MF: Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 46:63-69, 1997
13. Nestel PJ: High-density lipoprotein turnover. Am Heart J 113:518-521, 1987
14. Baynes C, Henderson V, Richmond W, Johnston DG, Elkeles RS: The response of hepatic lipase and serum lipoproteins to acute hyperinsulinemia in type II diabetes. Eur J Clin Invest 22:341-346, 1992
15. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC: Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 104:69-77, 1993
16. Frenais R, Ouguerram K, Maugeais C, Mahot P, Maugere P, Krempf M, Magot T: High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia. 40:578-583, 1997
17. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997
18. Pietzsch J, Wiedemann B, Julius U, Nitzsche S, Gehrisch S, Bergmann S, Leonhardt W, Jaross W, Hanefeld M: Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J Lipid Res 37:2074-2087, 1996
19. Tan KCB, Shiu SWM, Janus ED, Lam KSL: LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 129:59-65, 1997
20. Duque M, Graupner M, Stutz H, Wicher I, Zechner R, Paltauf F, Hermetter A: New fluorogenic triacylglycerol analogs as substrates for the determination and chiral discrimination of lipase activities. J Lipid Res 37:868-876, 1996
21. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke K-U, Hanefeld M: Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1254:77-88, 1995
22. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Julius U, Hanefeld M: Very fast ultracentrifugation of plasma lipoproteins avoids dissociation of apolipoproteins E and A-I (Abstract). Scand J Clin Lab Invest 55:A611, 1995
23. Pietzsch J, Nitzsche S, Wiedemann B, Julius U, Leonhardt W, Hanefeld M: Stable isotope ratio analysis of amino acids: the use of N(O)-ethoxycarbonyl ethyl ester derivatives and gas chromatography/mass spectrometry. J Mass Spectrom 30 (Suppl. 1):S129-S135, 1995
24. Pietzsch J, Julius U, Hanefeld M: Stable isotope ratio analysis of amino acids: the use of N(O)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 11:1835-1838, 1997
25. Cobelli C, Toffolo G, Foster DM: Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol 262:E968-E975, 1992
26. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr: Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 34:2207-2215, 1993
27. Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ: Apo AII kinetics in human using endogenous labeling with stable isotopes: slower turnover of apo AII compared with the exogenous radiotracer method. J Lipid Res 37:399-407, 1996
28. Matthews DE: Stable isotope methodologies in studying human amino acid and protein metabolism. Ital J Gastroenterol 25:72-78, 1993
29. Brewer HB Jr, Rader DJ: HDL structure, function and metabolism. Progr Lipid Res 30:139-144, 1991
30. Rader DJ, Ikewaki K: Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol 7:117-123, 1996
31. Rader DJ, Castro G, Zech LA, Fruchart J-C, Brewer HB Jr: In vivo metabolism of apolipoproteins A-I on high density lipoprotein particles LpA-I and LpA-II. J Lipid Res 32:1849-1859, 1992
32. Tailleux A, Fruchart J-C: HDL heterogeneity and atherosclerosis. Crit Rev Clin Lab Sci 33:163-201, 1996
33. Taskinen MR, Kahri J, Koivisto V, Shepherd J, Packard CJ: Metabolism of HDL apolipoprotein AI and All in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35:347-356, 1992
34. Ikewaki K, Zech LA, Kindt M, Brewer HB Jr. Rader DJ: Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 15:306-312, 1995
35. Tilly-Kiesi M, Lichtenstein AH, Joven J, Vililla E, Cheung MC, Carrasco WV, Ordovas JM, Dolnikowski G, Schaefer EJ: Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpA-I and LpA-I:A-II in older subjects. Arterioscler Thromb Vasc Biol 17:3513-3518, 1997
36. Brinton EA, Eisenberg S, Breslow JL: Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 84:262-269, 1989
37. Brinton EA, Eisenberg S, Breslow JL: Increased apoA-I and apoA-II fractional catabolic rate in patients with low high density lipoprotein cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87:536-544, 1991
38. Brinton EA, Eisenberg S, Breslow JL: Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlated inversely with estimates of HDL particle size. Arterioscler Thromb 14:707-720, 1994
39. Rainwater DL, Mitchell BD, Mahaney MC, Haffner SM: Genetic relationship between measures of HDL phenotypes and insulin concentrations. Arterioscler Thromb Vasc Biol 17:3414-3419, 1997
40. Tall AR: Plasma cholesteryl transfer protein. J Lipid Res 34:1255-1274, 1993
41. Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K: Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acids. Metabolism 46:1166-1170, 1997
42. Goldberg IJ, Blaner WS, Vanni TM, Moukides M, Ramakrishnan R: Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. J Clin Invest 86:463-473, 1990
43. Baynes C, Henderson V, Anyaoku V, Richmond W, Hughes CL, Johnston DG, Elkeles RS: The role of insulin sensitivity and hepatic lipase in the dyslipidemia of type 2 diabetes. Diabet Med 8:560-566, 1991
44. Ginsberg HN: Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14:839-855, 1991
45. Laakso M, Sarlund H, Mykkanen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223-231, 1990
46. Karhapää P, Malkki M, Laakso M: Isolated low HDL cholesterol: an insulin-resistant state. Diabetes 43:411-417, 1994
47. Sparks D, Frohlich JJ, Prit chard PH: Lipid transfer proteins, hypertriglyceridemia, and reduced high-density lipoprotein cholesterol. Am Heart J 122:601-607, 1991
48. Tato F, Vega GL, Grundy SM: Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 15:446-451, 1995
49. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, van Tol A: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188-194, 1994
50. Dullaart RP, Groener EM, Dikkeschei BD, Erkelens W, Doorenbos H: Increased cholesterol transfer activity in complicated type I diabetes mellitus: Its relationship with serum lipids. Diabetologia 32:14-19, 1989
51. Bagdade JD, Kelley DE, Henry RR, Eckel RH, Ritter MC: Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes 46:414-420, 1997
52. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91:1743-1752, 1993